{
}
Deutsche Bank has raised its price target for Alcon Inc. to CHF96 from CHF92, maintaining a Buy rating following the company's positive Capital Markets Day. Alcon, valued at $47.4 billion, anticipates organic sales growth of 6-8% and EPS growth of 12-15%, supported by upcoming product launches in surgical eye care and pharmaceuticals. Other analysts have also increased their targets, reflecting strong confidence in Alcon's innovative pipeline and long-term growth potential.
The Swiss stock market closed lower, impacted by US tariffs on cars and parts, with the SMI falling 0.7% to 12,867 points. UBS shares plummeted 4.1% after a downgrade by Bank of America, while Roche and other companies also faced losses. In contrast, Nestlé and Alcon saw gains due to positive developments in their business sectors.
Bank of America has upgraded Alcon (ALC) from neutral to buy, citing an impending earnings upgrade cycle fueled by new product launches. The price target for Alcon's stock has been raised from $92 to $108, indicating a potential upside of about 17%. Analyst Julian Wadhwa highlighted the stock's attractive valuation, as it trades below long-term averages, with growth expected from several new products this year.
The Swiss stock market remained positive following the Swiss National Bank's decision to cut its key interest rate by 25 basis points to 0.25%. Analysts expect this to be the last cut for the year, with inflation forecasts suggesting no need for further reductions. The SMI index rose by 0.11%, led by Nestlé, while Swissquote shares fell by 7.7% despite reporting a strong fiscal performance.
The Swiss stock market remained positive as the Swiss National Bank (SNB) cut its key interest rate by 25 basis points to 0.25%, a move anticipated by analysts. The SMI index rose by 0.11%, led by Nestlé and Alcon, while Swissquote shares fell 7.7% despite reporting a strong fiscal performance. HOCN shares surged 19% amid plans to appeal a delisting decision.
UBS recommends buying Swiss medtech stocks Alcon and Medacta, citing their growth potential despite short-term concerns for Alcon's 2025 forecasts. Alcon is expected to launch new products, while Medacta shows sustained growth in orthopaedics. Conversely, Straumann is rated sell due to high expectations and recent strong performance.
UBS benefits from a de facto state guarantee, leading to an estimated annual subsidy of CHF 2.6 billion due to reduced financing costs, according to a University of Bern analysis. Meanwhile, President Donald Trump is restructuring the Department of Justice, dismissing prosecutors involved in investigations against him and freezing funding programs, raising concerns over the separation of powers. In other news, Saïda Keller-Messahli faces defamation charges for her claims about Swiss mosques, and the Munich prosecutor's office investigates real estate mogul René Benko for fraud.
Alcon Inc. (VTX:ALC) has seen its stock decline by 8.5% over the past three months, despite respectable financials, including a return on equity (ROE) of 5.4%. While this ROE is below the industry average of 12%, the company achieved a significant net income growth of 65% over the last five years, surpassing the industry growth rate of 11%. Investors must now assess whether this growth potential is reflected in the current share price.
Redburn-Atlantic has upgraded Alcon Inc. to a Buy rating, raising the price target to CHF93.00, citing strong anticipated growth from new product launches and effective cost management. Alcon reported a 6% sales increase in Q3 2024, reaching $2.4 billion, with core EPS up 25% to $0.81. Additionally, Needham has set a price target of $108.00, highlighting Alcon as a top pick for 2025, while KeyBanc maintains an Overweight rating with a $107.00 target.
The Dry Eye Disease market is experiencing significant growth, driven by increased product demand and technological advancements. A comprehensive report analyzes market size, trends, competitive landscape, and future growth prospects, highlighting key players like Novartis AG and Alcon Inc. It also delves into consumption patterns, pricing strategies, and market segmentation across various applications and regions.
Alcon Inc.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Deutsche Bank raises Alcon price target amid strong growth projections and innovations
12:55 31.03.2025
Swiss stock market declines amid trade tensions and corporate earnings reports
United States Dollar
Idorsia Ltd
Nestle SA
Sika AG
Implenia AG
Adecco Group AG
Hoffmann-La Roche AG
Schindler Holding AG
Alcon Inc.
CHE
Show more
19:21 27.03.2025
Bank of America upgrades Alcon stock to buy amid growth prospects
15:35 25.03.2025
swiss stock market remains positive after snb interest rate cut
Swiss Franc
Novartis AG
Swissquote Group Holding Ltd
Nestlé S.A.
Julius Bär Gruppe AG
Holcim AG
Alcon Inc.
Hoffmann-La Roche AG
Adecco Group AG
RICHEMONT, Intellectual Property Services
The Swatch Group AG
Sonova R
Axon Partners Group, S.A.
Sandoz Group AG
CHE
Arthur Jurus
Karsten Junius
Philipp Merkt
Show more
11:36 20.03.2025
Swiss stock market remains positive after SNB interest rate cut
Swiss Franc
Novartis AG
Swissquote Group Holding Ltd
Nestlé S.A.
Hocn AG
Holcim AG
Alcon Inc.
Hoffmann-La Roche AG
Adecco Group AG
RICHEMONT, Intellectual Property Services
The Swatch Group AG
Sonova R
Axon Partners Group, S.A.
Sandoz Group AG
CHE
Arthur Jurus
Karsten Junius
Philipp Merkt
Show more
11:35 20.03.2025
ubs recommends buying alcon and medacta in swiss medtech sector
Swiss Franc
ConvaTec Group PLC
Medacta Group SA
Alcon Inc.
Straumann Holding AG
SIEMENS HEALTHINEERS
DEU
CHE
Graham Doyle
Show more
12:00 04.02.2025
state subsidies for UBS and trump's power restructuring in the us
Swiss Franc
RICHEMONT, Intellectual Property Services
Alcon Inc.
Novartis AG
Nestlé S.A.
Hoffmann-La Roche AG
USA
DEU
FRA
KOR
CHE
AUT
René Benko
Thomas Milz
Mirjam Moll
Donald Trump
Kash Patel
Show more
06:56 29.01.2025
alcon's stock decline raises questions despite strong earnings growth potential
12:48 13.01.2025
Alcon stock upgraded to buy as growth prospects improve with new launches
23:19 12.01.2025
dry eye disease market growth trends and competitive landscape analysis 2025 to 2032
07:17 10.01.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Finance Mergers & Acquisitions
Banking Regulations
Global Financial Events
Market Analysis and Predictions
Retail and Consumer Goods
Financial Scams and Security
CEO Changes
Global Trade Developments
Central Bank Actions
GDP Growth & Recession Forecasts
Government Policies
Hedge Funds & Private Equity
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Startups & Entrepreneurship
Workplace Trends
Government Economic Policies
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Bank of America Corporation
Wells Fargo & Company
Citigroup Inc.
Barclays PLC
Morgan Stanley
Deutsche Bank Money Market PP
Lloyds Banking Group plc
Huawei Technologies CO. Ltd.
American Express Company
Credit Suisse Strategic Income I
UBS Group AG
AMERICAN EXPRESS
Northern Trust Corporation
Berkshire Hathaway Inc.
Amazon.com, Inc.
Banco Santander, S.A.
Currencies:
United States Dollar
Euro
Chinese Yuan
Swiss Franc
British Pound Sterling
Indian Rupee
Japanese Yen
Canadian Dollar
Australian Dollar
Russian Ruble
Saudi Riyal
United Arab Emirates Dirham
Indonesian Rupiah
Hong Kong Dollar
Danish Krone
Offshore Chinese Yuan
Singapore Dollar
Ghanaian Cedi
Mexican Peso
South Korean Won
People: